Medicinal composition for treating diabetes

Abstract

The invention discloses a medicinal composition for treating diabetes, which has a function like that of insulin, and comprises a chromium salt and an adenosine phosphate, which are medicinal active ingredients accounting for 1 to 95 weight percent of the composition; the chromium salt is trivalent chromium salt which is pharmaceutically soluble; and the adenosine phosphate may be adenosine phosphate (AMP), adenosine diphosphate (ADP) or adenosine triphosphate (ATP), or may be a derivative of the AMP, a derivative of the ADP and a derivative of ATP, or may be 3',5'-cyclic adenosine monophosphate. The medicinal composition may also contain cysteine. The medicinal composition has a function like that of insulin, can directly promote the absorption of amylaceum, contributes to blood sugar control, promotes the normal glycometabolism of body and the normal lipid metabolism of the body and can be used for treating diabetes and diseases associated with the diabetes.

Description

technical field [0001] The invention belongs to the technical field of medicine and relates to a composition for treating diabetes. Background technique [0002] Diabetes mellitus is a comprehensive disease characterized by hyperglycemia, which is caused by the lack of insulin in the body or the inability to perform normal physiological functions or the disorder of glucose metabolism, which in turn leads to the disorder of protein, fat, water, electrolyte and other substances. Type I diabetes caused by the lack of insulin in the body mainly due to the destruction of pancreatic islet B cells and type II diabetes caused by the lack of activity of insulin in the body and unable to play a normal physiological role. Type I is usually treated with exogenous insulin supplementation, but there is still no effective treatment for type II; moreover, the current classic treatment methods are not satisfactory, and the treatment of type I diabetes by insulin injection increases the suffe...

AI Technical Summary

Problems solved by technology

[0005] In practical applications, inorganic chromium compounds have low fat solubility, low bioavailability, low activity and large doses, often accompanied by side effects such as gastrointestinal discomfort, nausea, vomiting, and diarrhea; the hypoglycemic effect of organic chromium compounds is generally Higher than inorganic chromium compounds, high fat solubility, strong cell penetration ability, reducing side effects and promoting the absorption of chromium compounds

Organic chromium compounds can theoretically be obtained by extraction or synthesis. Studies have found that glucose tolerance factor (GTF) also exists in Brewer's yeast. Scientists have been working on extracting and purifying GTF from Brewer's yeast and other yeasts. However, organic chromium is tightly combined with many active ingredients in Brewer's yeast, so it is difficult to extract these active ingredients, and none of them have been successful.

For the synthesis of organic chromium compounds, a series of research results at home and abroad show that the safety of Cr3+ completely depends on the properties of the ligands, so choosing a suitable carrier is the key to the function of chromium. Ligands mainly include biological small molecule amino acids and their derivatives, low-toxic organic carboxylic acids, etc., but these ligands have small molecular weights, and the slow-release effect is not significant after entering the body. In addition, organic carboxylic acids still have certain toxicity

Images